Improve early diagnosis of clinically significant prostate cancer. This working group will improve early diagnosis of clinically significant prostate cancer in a three-fold manner:

  • Improve the diagnostic pathway in secondary care using low-cost imaging (MRI / ultrasound) and further reductions in the number of patients requiring a biopsy and the total number of biopsies taken through risk models and nomograms.
  • Validate the accuracy and test the utility of novel imaging (biparametric MRI, PSMA PET, multi-parametric ultrasound) and AI tools (for pathology and imaging) in the diagnostic pathway.
  • Reduce the burden of repeated invasive biopsy whilst detecting progression of cancer early in patients with non-metastatic prostate cancer that is suitable for active surveillance.